Loading...
The glucagon-like peptide-1 analogue liraglutide (Saxenda) is approved for long-term management of obesity. In a previously published, multinational, manufacturer-sponsored trial, researchers randomized 3731 nondiabetic obese or overweight (body-mass index, >27 kg/m2) adults to daily subcutaneous liraglutide (3.0 mg) or placebo. All patients received lifestyle counseling. After 56 weeks, the liraglutide group had lost significantly more weight than the placebo group (mean decrease, 8.0% vs. 2.6% of initial body weight; NEJM JW Gen Med Aug 1 2015 and N Engl J Med 2015; 373:11).
To assess progression to diabetes in this cohort, researchers evaluated 2254 patients who were prediabetic at baseline (by American Diabetes Association [ADA] criteria…